Basic Coracten Information

• INN (International Nonproprietary Name): Nifedipine
• Brand Names Available In United Kingdom: Adalat and generics (Adalat formulations remain widely available in the EU and UK markets; generics listed as Nifedipine ER / Nifedipine CR)[1][3]
• ATC Code: C08CA05
• Forms & Dosages: Extended‑release tablets 30 mg, 60 mg, 90 mg; immediate‑release capsules 10 mg, 20 mg (less common); modified‑release tablets including 20 mg and 30 mg variants
• Manufacturers In United Kingdom: Original brand Bayer AG (Germany) and common generic manufacturers supplying UK market include Teva, Sandoz/Novartis, Mylan, Actavis, Apotex; local suppliers vary by product
• Registration Status In United Kingdom: Prescription‑only medicine with EU/EHA approvals historically maintained; prescribers should consult the Summary of Product Characteristics (SPC) for specific UK licences and MHRA guidance
• OTC / Rx Classification: Prescription‑only medicine (Rx)

Major 2022–2024 Studies

Which trial results matter for patients asking about coracten?

Recent randomised controlled trials and pooled analyses from 2022 to 2024 emphasise the clinical value of extended‑release nifedipine in long‑term care.

These trials show ER formulations produce meaningful systolic blood pressure reductions compared with placebo and maintain angina control comparable to other dihydropyridines.

Comparisons against amlodipine demonstrated non‑inferiority for short‑term blood‑pressure control in multiple randomised studies.

Extended‑release nifedipine also performed better than immediate‑release preparations for chronic therapy due to steadier plasma levels and fewer rebound events.

For people focused on angina symptoms, the ER evidence largely replicates older angina data while showing improved tolerability versus older IR regimens.

Overall, the modern ER evidence base supports using nifedipine ER for chronic hypertension and stable angina where a dihydropyridine is indicated.

Main Outcomes

What did the trials measure and find?

Typical starting ER doses of nifedipine (30 mg once daily) yielded consistent reductions in office and ambulatory systolic blood pressure compared with placebo.

Several trials reported non‑inferiority to amlodipine in short‑term BP control while maintaining similar angina frequency reductions.

Improvements in exercise tolerance and angina episodes mirrored older angina studies but were achieved with fewer peak‑related adverse events when ER formulations were used.

Safety Observations

What safety signals should clinicians and patients expect?

Across trials the common class adverse effects were peripheral oedema, headache, flushing and dizziness.

Immediate‑release use was linked to higher rates of reflex tachycardia and transient hypotension compared with ER forms.

Because nifedipine undergoes hepatic metabolism, trials and product documents recommend vigilance and monitoring in patients with liver impairment.

Layman’s Explanation

How does coracten work in plain terms?

Nifedipine relaxes the muscles that sit in the walls of small arteries so the vessels open wider.

Wider arteries mean lower blood pressure and reduced workload for the heart, which helps both hypertension and angina symptoms.

Scientific Breakdown

What is the pharmacology behind it?

Nifedipine is a dihydropyridine calcium‑channel blocker (ATC C08CA05).

It selectively blocks L‑type calcium channels in vascular smooth muscle, reducing intracellular calcium.

This reduction causes arteriolar vasodilation and lowers afterload, which in turn decreases myocardial oxygen demand.

Pharmacokinetics & Formulation Notes

Why pick ER over IR in most patients?

Extended‑release tablets (available in 30 mg, 60 mg and 90 mg strengths) provide a sustained plasma concentration that reduces peak‑to‑trough swings.

Those swings are what cause reflex tachycardia and symptomatic hypotension with immediate‑release products.

Hepatic metabolism predominates, so dose adjustments and liver‑function monitoring are indicated for significant hepatic impairment.

Downstream Effects

What clinical benefits and compensatory responses occur?

Reducing afterload lowers myocardial oxygen demand and benefits patients with chronic stable and vasospastic angina.

Reflex sympathetic activation can occur but is minimised when ER formulations are used instead of IR forms.

United Kingdom Approvals

What is coracten licensed for in UK practice?

Nifedipine is licensed and prescribed in the UK for hypertension and angina pectoris, including chronic stable and vasospastic angina.

The medicine is a prescription‑only product and is commonly supplied as extended‑release formulations such as Adalat and generics.

Notable Off‑Label Trends

When might clinicians use nifedipine outside its licence?

Specialist centres use nifedipine in paediatric settings for post‑transplant hypertension with weight‑based dosing of 0.25–0.5 mg/kg/day under close oversight.

Some obstetric units may use nifedipine for tocolysis in preterm labour under specialist protocols, but such use requires consultant supervision.

Formulation Selection By Indication

Which formulation suits which situation?

ER tablets (30–90 mg) are preferred for chronic blood‑pressure control and long‑term angina prophylaxis.

Immediate‑release capsules (10–20 mg) are sometimes used in hospital for acute angina but are less common and carry safety concerns for outpatient rapid BP lowering.

General Dosing

How is coracten typically started and adjusted?

Standard practice in the UK is to begin with nifedipine ER 30 mg once daily for hypertension or chronic angina.

Clinicians may titrate to 60–90 mg once daily according to response and tolerability.

The typical maximum ER daily dose is 90 mg.

Condition‑Specific Dosing

What do guidelines and SPCs recommend by condition?

For hypertension start with 30 mg ER once daily and maintain at 60–90 mg once daily if required for control.

For chronic stable or vasospastic angina similar ER dosing applies, titrated to symptom control and side‑effect profile.

Special Populations

Who needs extra caution?

Elderly patients should start lower and be titrated cautiously because of an increased risk of orthostatic hypotension and dizziness.

Hepatic impairment requires dose reduction and closer monitoring due to the drug's hepatic metabolism.

Renal impairment usually needs no routine dose adjustment, but blood pressure and renal function should be monitored.

Paediatric Dosing (Off‑Label)

How is nifedipine used in children when indicated?

Pediatric dosing is specialist supervised and typically 0.25–0.5 mg/kg/day in divided doses, rarely exceeding 3 mg/kg/day.

Such use is normally limited to specific contexts like post‑transplant hypertension and requires consultant paediatric input.

Contraindications

Who should not take coracten?

Absolute contraindications include known hypersensitivity to nifedipine or its excipients.

Other absolute contraindications are severe coronary artery disease, recent myocardial infarction (≤2 weeks), cardiogenic shock and severe aortic stenosis.

Concomitant rifampin use is contraindicated because it substantially reduces nifedipine exposure and efficacy.

Adverse Effects

What side effects are common and clinically important?

Common adverse effects include headache, flushing, peripheral oedema, dizziness or lightheadedness, fatigue and nausea.

Peripheral oedema is particularly frequent with long‑acting dihydropyridines and is a common reason for treatment change.

Monitoring & Mitigation

How should clinicians reduce risk?

Monitor blood pressure, heart rate and liver function at baseline and after dose changes.

In elderly or frail patients titrate slowly to reduce the risk of symptomatic hypotension.

Advise patients not to stop nifedipine abruptly and to taper under clinical supervision to avoid rebound hypertension or angina.

Food Interactions

Are there dietary warnings patients must follow?

Grapefruit juice inhibits CYP3A4 and can raise nifedipine plasma levels, so patients should avoid excessive grapefruit intake.

Taking ER tablets as labelled (usually once daily) reduces variability from food effects in everyday use.

Drug Combinations To Avoid

Which drug interactions are dangerous or clinically significant?

Rifampin substantially reduces nifedipine efficacy and is contraindicated with nifedipine use.

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole and certain macrolide antibiotics can markedly increase nifedipine exposure and may require dose adjustment or alternative therapies.

Antihypertensive Polytherapy

How does nifedipine fit in combination regimens?

Combining nifedipine with beta‑blockers, ACE inhibitors or diuretics is common practice but increases the risk of hypotension and requires monitoring.

Short‑acting immediate‑release nifedipine used with other vasodilators can precipitate dangerous hypotension; ER formulations are safer for chronic combination therapy.

Survey Data

What do UK patients say about coracten?

Primary‑care and cardiology clinic audits commonly report symptomatic improvement in blood‑pressure control and fewer angina episodes with ER nifedipine.

Side effects cause discontinuation in a minority, with peripheral oedema and flushing the most frequent reasons for stopping treatment.

Forum Trends

What themes appear in online patient conversations?

Common anecdotal reports include transient headaches and flushing when treatment starts, leg swelling developing over weeks, and better tolerance with ER formulations.

Patients often say activity tolerance and sleep improve once doses stabilise and side effects settle.

Practical Counselling Points

What should pharmacy staff tell patients at dispense?

Advise patients to report new shortness of breath, marked swelling, or symptoms of low blood pressure such as fainting or dizziness.

Missed‑dose advice: take as soon as remembered unless it is near the next dose, and do not double up.

Stress the importance of not stopping therapy suddenly and of regular BP checks with their GP.

Distribution & Market Structure

Who supplies coracten in the UK market?

The original brand is Bayer AG and multiple generics are supplied by manufacturers such as Teva, Sandoz/Novartis, Mylan, Actavis and Apotex.

Products are marketed as Adalat, Adalat CC and generics labelled as Nifedipine ER or Nifedipine CR in EU/UK labelling.

Packaging in the EU/UK commonly uses 28 or 30‑tablet blister packs for ER tablets.

Packaging & Forms

What strengths and formats are commonly dispensed?

Common ER strengths are 30 mg, 60 mg and 90 mg, supplied in blister packs of 28 or 30 tablets.

Immediate‑release capsules of 10 mg and 20 mg are less common in community practice.

Pricing & Procurement

How does cost influence prescribing in the UK?

On the NHS generic nifedipine ER is cost‑effective and widely prescribed where appropriate.

Private and online pharmacies list branded and generic ER products; ensure supplies are MHRA‑licensed and dispensed to a valid prescription.

In our online pharmacy, coracten is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparison Table (Text)

Which alternatives are commonly considered against nifedipine?

Amlodipine (C08CA01): longer half‑life with gradual onset, once‑daily dosing and generally less reflex tachycardia; similar efficacy for blood pressure control.

Felodipine: similar dihydropyridine profile but less commonly used in UK primary care.

Nicardipine: used intravenously in acute care; oral options exist but selection depends on clinical scenario.

ACE Inhibitors/ARBs: alternative classes for hypertension with additional cardioprotective benefits and a different mechanism of action.

Pros And Cons

What are the practical advantages and limitations?

Nifedipine ER advantages include effective vasodilation, reliable angina control and the availability of multiple ER strengths (30/60/90 mg).

Drawbacks include a relatively higher incidence of peripheral oedema compared with some alternatives and the need for careful dosing in hepatic impairment.

Choosing Therapy In UK Practice

How do clinicians decide between nifedipine and alternatives?

Choice is driven by comorbidities, tolerability, drug interactions and cost considerations.

Amlodipine is often selected for smoother haemodynamics, but nifedipine remains valuable for certain angina subtypes and in patients who respond better to it.

Historical Approvals

When was nifedipine first approved and how is it regulated now?

Nifedipine was first approved by the US FDA on 31 December 1981.

Branded Adalat products remain approved and widely distributed in the EU and many global markets, while Adalat CC was discontinued as a brand in the US though generics persist.

UK Regulatory Context

What must prescribers in the UK check?

Nifedipine formulations are prescription‑only in the UK, and following EU exit the MHRA continues licensing processes for marketed products.

Prescribers should favour MHRA‑approved or UK‑licensed generics where possible and consult the SPC for product‑specific guidance.

Labelling & SPCs

Where to check up‑to‑date details?

Consult the Summary of Product Characteristics (SPC) for each marketed formulation to confirm contraindications, interactions and dose adjustments before prescribing.

Consolidated FAQ

What do patients ask most often about coracten?

Q: Can I stop nifedipine suddenly?

A: No — abrupt cessation can worsen angina or hypertension; taper under clinical supervision.

Q: What if I miss a dose?

A: Take as soon as remembered unless it is close to the next dose; do not double up.

Q: What should I do in case of overdose?

A: Overdose may cause profound hypotension and cardiac disturbances; seek urgent medical attention for supportive monitored care.

Q: Is nifedipine safe in pregnancy?

A: It is used in specialist settings for pregnancy hypertension or tocolysis but requires specialist oversight and obstetric guidance.

Q: Which formulation is best for chronic use?

A: ER formulations (30–90 mg options) are standard for chronic hypertension and angina because they give steady plasma levels and lower adverse‑event risks compared with IR forms.

Suggested Visuals For Clinical And Patient Materials

What images help patients and clinicians understand coracten quickly?

• Packshot of ER tablet blister labelled "Nifedipine 30 mg Film‑Coated Tablets" to show typical EU/UK 28/30 pack formats.
• Infographic of mechanism: L‑type channel blockade → arteriolar vasodilation → reduced afterload.
• Dosing ladder graphic: start 30 mg ER → titrate to 60–90 mg ER; include flags for elderly and hepatic impairment.
• Side‑effect icon set: peripheral oedema, headache, flushing, dizziness; monitoring checklist for BP and liver function.

Accessibility note: Use large font, plain language and alt text for all visuals and reference the SPC where required for clinician copies.

Storage And Transport

How should nifedipine be stored and handled?

Store at controlled room temperature, 20–25°C, protected from light and moisture.

Keep tablets in their original packaging until use to preserve ER integrity.

Pharmacies and wholesalers should maintain labelled, temperature‑stable conditions and avoid prolonged heat exposure that could affect the modified‑release matrix.

Advise patients to store medication in a cool dry place away from bathrooms and to discard after expiry.

Cold chain storage is not required, but avoid extremes of temperature.

For travel recommend keeping medication in hand luggage to prevent temperature extremes and ensure continuity of supply.

Prescribing Checklist For UK Practice

What should prescribers confirm before issuing coracten?

Confirm the indication (hypertension or angina), review absolute contraindications such as recent MI or cardiogenic shock, and check baseline blood pressure and heart rate.

Assess liver function and review any concurrent CYP3A4 modulators that could interact with nifedipine.

Titration And Monitoring

How should therapy be started and reviewed?

Start ER 30 mg once daily, review response and adverse effects after 2–4 weeks, and titrate to 60–90 mg once daily as required.

Monitor for peripheral oedema, symptomatic hypotension and any signs of heart‑failure decompensation.

Patient Counselling Bullets

• Take at the same time each day and avoid grapefruit juice.
• Report dizziness, fainting or breathlessness promptly.
• Do not stop the medicine suddenly — consult the prescriber for a taper plan.
• Bring medication to appointments for reconciliation and bring blood‑pressure readings if available.

Specialist Referrals & Red Flags

When to escalate care?

Refer to cardiology for unstable or worsening angina or if there is difficulty controlling blood pressure despite optimal doses.

Avoid using immediate‑release nifedipine for rapid BP reduction outside hospital settings and consult hepatology if significant liver disease complicates dosing decisions.

Delivery Across United Kingdom